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.2011.12.0Abstract The objective of this study was to develop paclitaxel (PTX) loaded poly(e-caprolactone)
(PCL) based tiny implants. b-Cyclodextrin (b-CD) and polyethylene glycol (PEG 6000) were used
to enhance solubility and release of the drug in the phosphate buffer saline pH 7.4. Implants were
evaluated in terms of color, shape, thickness, surface area, weight, drug content. Developed
implants were characterized for their surface morphology (SEM analysis), drug physical state by
thermal analysis (DSC studies), crystalline nature (XRD studies) and drug excipients compatibility
(FT-IR spectroscopy). Macroscopically all the tiny implants were white in color and cylindrical in
shape with smooth surfaces. PTX was entrapped within implants in the polymeric amorphous form.
In vitro drug release studies showed prolonged and controlled release of PTX with zero order and
Korsmeyer–Peppas model being exhibited. Excipients and method of preparation did not affect
chemical stability of PTX.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Chemotherapy of cancer involves use of chemotherapeutical
agents that are directed to kill or control the growth and pro-epartment of Pharmaceutics,
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02liferation of cancer cells. These agents are often toxic or even
life threatening. Cancer chemotherapy was ﬁrst successfully
practiced in the 1950s when nitrogen mustard was found to
be effective in inhibiting tumor growth. Due to its extreme tox-
icity, however, effective chemotherapy with anticancer drugs
was not widely applied until the 1960s. Despite aggressive ther-
apy using conventional treatment (surgical resection, radiation
and chemotherapy), the median reported survival rate has not
changed signiﬁcantly over the past three decades and remains
less than 1 year (Avgeropoulos and Batchelor, 1999).
Paclitaxel is a naturally occurring microtubule-binding
agent, which has been shown to have tumoricidal activity
against several human neoplasms, including non-small lung
cancer, breast cancer, ovarian cancer and brain cancer. Paclit-
axel (PTX) has been proven to exhibit signiﬁcant activities inier B.V. All rights reserved.
Table 1 Composition of the formulations.
Ingredients P1 (mg) P2 (mg) P3 (mg) P4 (mg)
PTX 6 9 6 9
b-CD 6 9 – –
PEG-6000 – – 6 9
PCL 18 12 18 12
86 J.G. Hiremath et al.clinical trials against a wide spectrum of cancers (Rowinsky
et al., 1992; Spencer and Faulds, 1994). Since, PTX is insoluble
in water; the clinically available PTX injection used an emulsi-
ﬁer reagent called Cremophor EL (Singla et al., 2002). This has
been found to cause serious side effects (Weiss et al., 1990;
Dorr, 1994). The primary goal of formulation development
for PTX was to eliminate the Cremophor EL. Polymeric
implant may provide an ideal solution to the problem by elim-
inating the use of such adjuvant.
Biodegradable polyesters derived from lactic acid, glycolic
acid and e-caprolactone have gained much interest in biomed-
ical research for the delivery of various drugs. Attention was
drawn to poly(e-caprolactone) (PCL) owing to its numerous
advantages over other biodegradable polyesters. This led to
its application in the preparation of different delivery systems
in the form of implants, microspheres and nanoparticles
(Ramesh et al., 2002; Sinha et al., 2004).
The production of drug loaded polymeric implant, wafer,
microspheres and hydrogels has introduced a new concept in
drug administration. Drugs can be delivered to tumor in a
sustained, continuous and predictable release fashion using
polymers as delivery vehicles. The implantable and intratu-
moral injectable microspheres drug delivery systems commer-
cially available for the treatment of prostate cancer are
Decapeptyl (d-Trp) LH-RH, Lupron Depot (Leuprolide),
Zoladex (D-ser(Bu), AzGly-GnRH and local delivery Glia-
del (Carmustine) for brain tumor.
The development of implantable drug delivery systems is
perhaps the most widely investigated application of biodegrad-
able polymers. Due to their transient nature, biodegradable
polymers do not require surgical removal after their intended
application and thus can circumvent some of the problems re-
lated to the long-term safety of non-degradable implanted de-
vices. Drug release from a biodegradable matrix type implant
device occurs by one or a combination of mechanisms viz.,
erosion of the matrix, diffusion through the matrix or combi-
nation of both diffusion and erosion mechanisms (Horikoshi
et al., 1997). The present research work was aimed to prepare
PTX loaded biodegradable polymeric implants by melt tech-
nology and carry out their in vitro characterization.
2. Materials and methods
2.1. Materials
Poly(e-caprolactone) (Mn 90,000) was purchased from Sigma–
Aldrich, Bangalore, India. PTX was obtained as a gift sample
from Naprod Life Sciences Pvt. Ltd., Mumbai, India. b-Cyclo-
dextrin, PEG-6000, sodium chloride, sodium dihydrogen
orthophosphate, potassium dihydrogen orthophosphate were
purchased from SD Fine Chemicals, Mumbai, India. All other
reagents and solvents were of an analytical grade.2.2. Methods
2.2.1. Preparation of the PTX loaded biodegradable polymeric
implants
Implants were prepared by melt method. Polymer (PCL) was
melted on a hot plate below its glass transition temperature
(60 C). As the polymer starts melting at its glassy state, pre-
viously triturated drug (PTX) and PEG-6000 were mixed hom-
ogenously into molten polymer. Next, temperature was
reduced slowly to 42 C; during this time, uniform cylindrical
implants were prepared by using two ﬂattened stainless steel
rods. Implants with b-CD and blank (without drug) were
prepared in the same manner. The composition of the formu-
lations and photographs is shown in Table 1 and Fig. 1,
respectively.
2.3. Physicochemical evaluation of implants
Prepared implants were characterized for their physicochemi-
cal parameters like weight, color, shape, height and area.
The implant diameter (d) and height (h) were measured by
using digital vernier calipers and area calculated using the for-
mula [2pr(r+ h)].
2.3.1. Estimation of drug content
The extraction procedure was employed for the determination
of PTX content in implants. Implant was dissolved in 15 ml of
dichloromethane (DCM). PBS pH 7.4 and ethanol (1:9 v/v,
10 ml) mixture was introduced to this solution. DCM was
evaporated completely and solution was then ﬁltered using
0.22 lm nylon membrane (Millipore, Bangalore, India) and
suitably diluted with PBS pH 7.4 and ethanol mixture. The
PTX content was determined at 229.60 nm using double beam
UV–Visible spectrophotometer against ethanol and PBS 7.4
mixture as a blank solution.
2.3.2. Fourier transform infrared analysis (FT-IR)
The FT-IR spectral measurements of pure PTX, polymer,
carrier, physical mixtures and formulations were taken at
ambient temperature using a FT-IR spectrophotometer (Per-
kin Elmer, Japan). About 5 mg of samples were mixed with
KBr and vacuum-packed to obtain pellets of the material.
The implant samples were cast onto NaCl plates from solu-
tion in dichloromethane, which were analyzed. All the spectra
acquired scans between 400 and 4000 cm1 at a resolution of
4 cm1.2.3.3. Thermal analysis (DSC)
Differential scanning calorimetry analysis (DSC) of pure drug,
polymer, carrier, physical mixtures and formulations was con-
ducted using DSC 822e (Mettler Toledo star system). Samples
were weighed (2.00–5.00 mg) and placed in sealed aluminum
pans. The coolant was liquid nitrogen. The samples were
scanned at a rate of 10 C/min from 10 to 230 C.
2.3.4. X-ray diffraction analysis (XRD)
X-ray diffraction patterns of the pure PTX, polymer, carrier,
physical mixtures and drug loaded PCL implants (by using
sample holder grid technique) were determined using a Bruker
AXS D8 Advance diffractometer, equipped with a rotating
Figure 1 PTX loaded implants.
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of scans was from 0 to 60 and the scan speed was 2 per min-
ute at increments of 0.02.
2.3.5. Surface morphology (SEM)
Blank and drug loaded implants, immediately after manufac-
turing and after in vitro drug release were subjected to surface
morphology studies using scanning electron microscopy
(SEM). The polymeric implants were ﬁrst dried under vacuum.
Samples were glued to aluminum sample holders and gold
coated under argon atmosphere. The coated samples were
ﬁnally analyzed using scanning electron microscope (JSM
848, Joel, Japan) under suitable magniﬁcations.
2.3.6. In vitro drug release studies
The in vitro release studies of PTX implants were carried out at
37 ± 2 C in PBS pH 7.4 with 10% v/v of ethanol for a period
of 30 days (Hiremath et al., 2007). A horizontal water bath
shaker (Remi Instruments, India) was used to conduct
in vitro release studies. The screw capped bottles (60 ml vol-
ume), containing PTX implants in 50 ml of PBS pH 7.4 and
ethanol were ﬁxed onto the platform in waterbath. The plat-
form was mechanically shaken in horizontal direction at an
average speed of 100 rpm to induce mixing in the release med-
ium. At predetermined intervals of 24 h, release medium was
withdrawn and replaced with fresh 50 ml of medium to provide
the necessary sink condition. Withdrawn samples were diluted
suitably, ﬁltered (0.22 lm, Nylon membrane, Millipore, Ban-
galore, India) and analyzed PTX, UV-Spectrophotometrically.
The cumulative percentage drug release was calculated to
establish the drug release proﬁle of the implants.
2.4. Stability studies
The stability studies were carried out as per ICH guidelines for
a period of 3 months. The samples were stored at temperature
5 ± 3 C & 30 ± 2 C with 65 ± 5% (RH) in a stability cham-ber (GMG, India). At predetermined interval of 15, 30, 60 and
90 days, implant samples were analyzed for diameter, surface
area and its drug content.3. Results and discussion
3.1. Physicochemical characterization of implants
PTX loaded PCL implants were prepared by melt method
using. b-CD and PEG-6000 were added to improve release
characteristics of the drug from polymer matrices. Tempera-
ture was kept 60 C to avoid the degradation and interaction
of drug and excipients. Macroscopically, all the developed
implants were cylindrical in shape with smooth surfaces and
similar in appearance. Prepared implants were white in color.
Thicknesses of the implants were measured by using digital
Vernier Calipers and surface area was determined.
The results of physicochemical characterizations are illus-
trated in Table 2.
3.2. FT-IR analysis
Fig. 2 shows theFT-IRspectraofpuredrug,polymerand formu-
lations. Strong bands of pure PTX were observed at 2965 cm1
(‚C–H), 1707 cm1 (C‚O group), 1641 cm1 (C–C stretch),
1370 cm1 (CH3 bending), 1248 cm
1 (C–N stretch), 1072 cm1
(C–O stretch) and 709 cm1 (C–H off the plane). Bands of PCL
were observed at 2948 cm1 (C–H sp3) and 1729 cm1 (lactones).
PTX loaded implants P1 and P3 shows bands at 2948
cm1 and 1729 cm1 for C–H sp3 andC‚Ostretch, respectively,
drug peaks were disappeared in formulations due to which drug
was completely entrapped in the polymer or polymeric amor-
phous surface (Anand and Ramesh, 2004). Results of FT-IR
studies revealed no evidence of chemical or physical interaction
of drug and excipients. PTX entrapped within the polymer
matrix of PCL without chemical changes and interaction.
Figure 2 Transmission FTIR spectra of pure PTX (A), pure
PCL (B), b-CD (C), PEG-6000 (D), physical mixture (E), P1 (F)
and P3 (G). All the spectra acquired scans between 400 and
4000 cm1 at a resolution of 4 cm1.
Table 2 Physicochemical properties of PTX loaded implant.
Formulations P1a P2a P3a P4a
Theoretical PTX loading (% w/w) 20 30 20 30
Weight of implants (mg) 28.90 ± 0.820 29.63 ± 0.400 27.69 ± 0.95 28.5 ± 0.29
Color White White White White
Shape Cylindrical Cylindrical Cylindrical Cylindrical
Surface area (cm2)b 0.2218 ± 0.003 0.2190 ± 0.003 0.1992 ± 0.014 0.1928 ± 0.058
Thickness (D) (cm) 0.153 ± 0.001 0.156 ± 0.002 0.147 ± 0.025 0.145 ± 0.002
Drug content (%) 93.93 91.74 91.50 90.30
a Average of three determinations (±SD).
b Area = 2pr(h+ r), where r is the radius and h is the height.
Figure 3 DSC thermograms of pure PTX (A), pure PCL (B),
PEG-6000 (C), b-CD (D), physical mixture (E), P1(F) and P3 (G).
The experiment was carried with crimped aluminum pans and a
heating rate of 10 C/min and the samples were scanned at 10 C/
min from 10 to 230 C.
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The generated DSC thermograms are shown in Fig. 3. A sharp
endothermic peak of pure PTX, PCL, carriers, physical
mixture and formulations was obtained at 224.16, 69.66,
61.17, 61.16, 61.33 and 61.33 C, respectively (Zhang et al.
2010). For DSC studies samples were heated from 0–230 C
to avoid the chemical changes in PTX and PCL, hence there
was no peak observe for b-CD (melting point is 255–260 C,
we have scanned only up to drug melting point, due to chances
of drug degradation above 230 C). The generated DSC ther-mograms and their respective endothermic values indicated
that the drug and the method of preparation of implant had
little effect on the thermal properties of the polymer. However,
drug peak did not appear which probably may be due to
conversion of PTX from crystalline state to amorphous or
dissolution during the heating involved in the preparation of
Figure 4 XRD patterns of pure PTX (A), pure PCL (B), b-CD
(C), PEG-6000 (D), physical mixture (E), P1 (F) and P3 (G). The
range (2h) of scans was from 0 to 60 and the scan speed was 2
per minute at increments of 0.02.
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temperature and a slow rate of cooling enable the chains to
be mobile and to realign themselves may be resulting in a semi-
crystalline or amorphous nature or drug may be present in the
polymeric amorphous surface.3.4. XRD studies
Crystalline forms can be described as an arrangement of
molecular chains that result in ordered structure. Mostly poly-
mers exhibit either crystalline, semi crystalline or amorphous.
Crystalline polymer such as PCL contains crystalline regions.
Parameters that inﬂuence the crystallinity of a polymer are
those that provide polymeric molecular chains to reorganize
themselves into a more-ordered, and thereby lower the energy
state.
Elevated temperature and a slow rate of cooling enable the
chains to be mobile and to realign themselves in a more or-
dered solid structure. Thus, crystallinity of PCL polymer can
be altered as a result of heat involved in the melt method, as
well as the degree of crystallinity also depends upon the rate
of cooling during solidiﬁcation from the melt.
Fig. 4 illustrates the XRD spectra of pure PTX, polymer,
physical mixture and developed implants. Sharp peaks were
obtained at 5.35, 9.53, 10.81, 11.92, 12.90, 25.089, 42.16 (2h)of pure PTX. PCL showed peaks at 30.24, 33.86 (2h) (Liu
et al., 2011). Peaks of b-CD and PEG were obtained at
20.94 and 19.01/23.67 (2h). Physical mixture peaks were
found at 5.35, 12.90, 19.01, 20.94, 25.09, 30.24, 42.16 (2h).
However in case of drug loaded implants peaks were obtained
at 30.24, 33.86 (2h). Absence of drug peak in developed
implants further justiﬁed the presence of drug in the form of
amorphous or dissolution state.
3.5. Surface morphology (SEM)
Surface morphology of the implants immediately after manu-
facturing was found to be homogenous, uniform and smooth
in surface as shown in Fig. 5A and B. Samples P1, P2, P3
and P4, after 30 days of in vitro released were subjected to
SEM, showed porous surface and random fractures like cracks
and crevices (clusters and network ﬁbers) on the surface Fig. 5
P1(C), P2(D), P3 (E) and P4 (F), respectively. Importantly, the
implants were intact even on the 30th day and very less shrink-
age in the implant dimension was observed. Pores and chan-
nels were found more in the b-CD containing formulations
when compared to the formulations containing PEG-6000.
b-CD was not liqueﬁed completely during the preparation of
implants (due to its high melting point), while PEG-6000 was
completely melted which may cause, rechain orientation of
chemical structure, after solidifying to rigid implants. The
pores in the SEM were likely to be the voids left by the released
drug particles.
3.6. In vitro drug release studies
Fig. 6 shows the in vitro drug release proﬁle of implant formu-
lations. Release proﬁle demonstrated the initial small burst ef-
fect phase followed by slow and constant drug release. Initial
small burst effect phase was considered as a result of rapid dif-
fusion/dissolution of drug particles at the solid liquid interface.
The magnitude of burst effect was dependent on the propor-
tion of PTX on the outer surface of the implant. The cumula-
tive percentage of drug released from the P1, P2, P3 and P4
after 30 days was found to be 79.00 ± 2.68, 79.96 ± 2.78,
62.05 ± 1.49 and 66.16 ± 1.30%, respectively. The drug re-
leased from PCL implants was primarily by diffusion through
the various drug-diffusing channels developed on the implant
surface as observed in SEM. PTX has very low water solubility
and resists diffusion from the hydrophobic polymer to the
aqueous medium. The slow and controlled release of the drug
from the implants is due to the high afﬁnity of the drug for the
hydrophobic matrix and the low solubility of the drug in the
aqueous medium.
As the content of PTX in the implant is higher, the formu-
lation becomes more hydrophobic and does not allow water to
penetrate and dissolve the drug and release of drug (Shikanov
et al., 2005).
Table 3 illustrates the release kinetic data obtained from the
release proﬁle of implants. Zero order and Korsmeyer–Peppas
model gave a good ﬁt for the drug release proﬁles of all im-
plants with greater regression coefﬁcients in comparison to
other models. The ﬁtting of these data to the Korsmeyer–Pep-
pas model demonstrated that drug release occurs mainly
through diffusion and erosion processes. Since the value of n
was in between 0.85 and 0.98, it indicated anomalous transport
(Costa and Lobo, 2001).
Figure 5 SEM of implants: Immediately after manufacturing (A) blank, (B) drug loaded implant and after 30 days of release studies (C)
P1, (D) P2, (E) P3 and (G) P4.
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Stability studies of the formulations containing PTX were con-
ducted to determine the effect of excipients and method of
preparation on the stability of the drug. At the end of 90 days
of stability studies slight changes in the diameter, surface area
due to the softening of the polymer on the surface of the
implant and negligible change in the drug content (±2%) were
observed. Thus, it can be concluded that the excipients andmethod of preparation does not alter the chemical stability
of drug entrapped in the PCL implants.
5. Conclusion
PTX loaded PCL implants were successfully prepared by
melt method with PEG-6000 and b-CD and its in vitro
characterization was carried out. The obtained results
indicated that the PCL implants can be potentially used for
Figure 6 In vitro release of PTX from the PCL based implants in
PBS pH 7.4 with 10% v/v of ethanol. (P1) (m) 20% drug loaded
implant with b-CD, (P2) (¤) 30% drug loaded with PEG-6000,
(P3) (d) 20% drug loaded with b-CD and (P4) (n) 30% drug
loaded implant with PEG-6000. Each point represents the average
of six determinations (n= 6).
Table 3 Release rate kinetics data of implant formulations.
Formulation code Regression (R2)
Zero
order
First
order
Higuchi
equation
Korsmeyer–Peppas
P1 0.9995 0.9565 0.9643 0.9951 (n= 0.910)
P2 0.9965 0.9415 0.9472 0.9860 (n= 0.904)
P3 0.9951 0.9927 0.9811 0.9952 (n= 0.855)
P4 0.9912 0.9523 0.9296 0.9827 (n= 0.984)
Paclitaxel loaded carrier based biodegradable polymeric implants 91sustained release of hydrophobic drug such as PTX. It can be
concluded that drug loaded implant appears to be a promis-
ing treatment modality for brain cancer. However, the
continuous release of an anticancer agent from a controlled
delivery device for 1 week to 1 month is usually required
for effective treatment of the brain cancer. Optimizations of
formulations with in vivo studies are required for the
assessment of this formulation as an effective dosage form
for PTX to be used for the effective treatment of brain
cancer.Acknowledgements
The authors thank to Ravikiran C.N., Secretary, East West
Group of Institution and Prof. Sridhar K.A. Principal, Dept.
of Pharmacology, East West College of Pharmacy, Bangalore,
India for their continuous support for the research work. The
authors also thank to Naprod Life Sciences Pvt. Ltd., Mum-
bai, India, for providing the gift sample of paclitaxel.
References
Anand, B.D., Ramesh, P., 2004. Development and characterization of
biodegradable chitosan ﬁlms for local delivery of paclitaxel. AAPS.
J. 6 (3), 27.
Avgeropoulos, N.C., Batchelor, T.T., 1999. New treatment strategies
for malignant gliomas. Oncologist 4, 209–224.
Costa, P., Lobo, J.M.S., 2001. Modelling and comparison of disso-
lution proﬁles. Eur. J. Pharm. Sci. 13, 123–133.
Dorr, R.T., 1994. Pharmacology and toxicology of cremophor EL
diluent. Ann. Pharmacother. 28, S11–S14.
Hiremath, J.G. et al., 2007. Biodegradable Poly (sebacic acid-co-
ricinoleic-ester anhydride) tamoxifen citrate implants: Preparation
and in vitro characterization. J. Appl. Polymer. Sci. 107, 2745–2754.
Horikoshi, S., Sato, H., Wang, M.Y., 1997. In-vitro and in-vivo
evaluation of taxol release from poly (lactic-co-glycolic acid)
microspheres containing isopropyl myristate and degradation of
the microspheres. J. Control. Release. 49, 157–166.
Liu, X. et al., 2011. Evaluation of two polymeric blends (EVA/PLA
and EVA/PEG) as coating ﬁlm materials for paclitaxel-eluting stent
application. J. Mater. Sci. 22, 327–337.
Ramesh, D.V. et al., 2002. Microencapsulation of FITC-BSA into
poly(e-caprolactone) by a water-in-oil-in-oil solvent evaporation
technique. Trends Biomater. Artif. Organs. 15, 31–36.
Rowinsky,E.K. et al., 1992. Taxol: the ﬁrst of the taxanes, an important
new class of antitumor agents. Semin. Oncol. 1992 (19), 646–662.
Shikanov, A. et al., 2005. Poly(sebacic acid-co-ricinoleic acid) biode-
gradable carrier for paclitaxel-effect of additives. J. Control.
Release. 105, 52–67.
Singla, A.K. et al., 2002. Paclitaxel and its formulations. Int. J.
Pharm. 235, 179–192.
Sinha, V.R. et al., 2004. Poly-epsilon-caprolactone microspheres and
nanospheres: an overview. Int. J. Pharm. 278, 1–23.
Spencer, C.M., Faulds, D., 1994. Paclitaxel. A review of its pharma-
codynamic and pharmacokinetic properties and therapeutic poten-
tial in the treatment of cancer. Drugs 48, 794–847.
Weiss, R. et al., 1990. Hypersensitivity reactions from taxol. J. Clin.
Oncol. 1990 (8), 1263–1268.
Zhang, Y. et al., 2010. A novel paclitaxel-loaded poly(&lt;epsilon>
caprolactone) / Poloxamer 188 blend nanoparticle overcoming multi-
drug resistance for cancer treatment. Acta. Biomed. 6, 2045–2052.
